A clinical trial is a research study in which patients volunteer to test the effectiveness of a technique to diagnose a medical condition or a treatment for it. Clinical trials are vital tools to help scientists and researchers find new ways to identify Alzheimer’s Disease and to develop new drugs that can improved the course of this neurodegenerative disease. The effects of this degenerative condition or treat its symptoms.Not all individuals are eligible for clinical trials, but those who are and agree to take part after discussions with their doctors are making important contributions to medical science.
Montefiore and Burke offer access to a number of clinical trials testing diagnostic techniques and treatment methods for Alzheimer’s Disease.
The CAB and Burke are sites for the Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) study, which is designed to assess the clinical usefulness and impact on outcomes of a brain PET scan that detects amyloid plaques in patients with mild cognitive impairment or dementia of uncertain cause. The study is led by the Alzheimer’s Association and the American College of Radiology Imaging Network (ACRIN) and managed by the American College of Radiology (ACR).
For more information about the IDEAS study, go to:
Other current clinical trials available through the CEAD include:
- Benfotiamine in Alzheimer’s Disease, a 12 month, Phase III, double-blind placebo controlled trial to determine if enhancing brain glucose utilization by increasing thiamine availability with benfotiamine treatment can slow the cognitive decline in patients with Amnestic Mild Cognitive Impairment (AMCI) or mild AD dementia by increasing thiamine availability. The trial is sponsored by the National Institute of Aging (NIH) and the Alzheimer’s Disease Discovery Fund(ADDF). Burke is the only site involved in this study.
- A 72-week Phase III Safety and Efficacy Study of AlZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease, is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. Subjects will be randomly assigned to the Group I arm, which will consist of ALZT-OP1a for inhalation, plus an oral placebo tablet; orthe Group II arm, which will consist of ALZT-OP1combination therapy ALZT-OP1a, plus ALZTOP1b for oral administration; orto the Group III arm, which will consist of inhaled placebo, plus ALZT-OP1b for oral administration; orto the Group IV placebo arm, which will consist of inhaled placebo plus an oral placebo tablet. This is a multi-center trial sponsored by AZ Therapies Inc.
- A Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo. This is a 16 week, multi-centered trial sponsored by Avanir Pharmaceuticals, Inc.
For more information about these trials, call Montefiore at 914-375-4880 or Burke at 914-597-2307.
The National Institutes of Health has extensive information on Alzheimer’s Disease trials at click here
The Alzheimer’s Association also has a listing of clinical trials at click here